The Medical Director role will be responsible for supporting the product through its life cycle for hidradenitis suppurativa (HS) via leadership, mentorship, and execution of the Medical Affairs strategic vision. Together with the Executive Director of Medical Affairs, this role will be responsible for supporting all relevant commercialization activities including launch activities for HS. This individual will play a meaningful role in engagement of the external medical community.
Job listings
USD/year
USD/year
This role focuses on the rare bone disease franchise, specifically preparing for the potential commercialization of a monoclonal antibody therapy for Osteogenesis Imperfecta (OI) and supporting Crysvita for XLH. Reporting to the VP Global/US Medical Affairs and Strategy, the Executive Director will establish partnerships with key opinion leaders, lead scientific education, and provide strategic medical expertise to the program and commercialization teams.